FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to a rodent containing a sequence characterized in expansion of hexanucleotide repeats at endogen locus C9orf72, as well as to its cell, embryo and motor neuron. An immortalized cell line containing a sequence characterized in expansion of hexanucleotide repeats at endogen locus C9orf72 is also disclosed. The invention also relates to a method for obtaining the above-mentioned rodent, providing for modification of a rodent genome to contain a sequence characterized in expansion of hexanucleotide repeats at endogen locus C9orf72.
EFFECT: invention is effective for identification of a candidate therapeutic agent for the treatment of a disease or condition associated with the presence of the sequence characterized in expansion of hexanucleotide repeats.
52 cl, 12 dwg, 10 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUND FOR MODULATION OF C9ORF72 GENE EXPRESSION AND USE THEREOF | 2013 |
|
RU2730677C2 |
| ANIMALS, OTHER THAN HUMANS, WITH DISTURBANCE IN LOCUS C9orf72 | 2016 |
|
RU2823721C2 |
| NON-HUMAN ANIMALS WITH DISTURBANCE IN LOCUS C9ORF72 | 2016 |
|
RU2725737C2 |
| NON-HUMAN ANIMALS CONTAINING THE HUMANIZED ASGR1 LOCUS | 2018 |
|
RU2796949C2 |
| ANIMALS OTHER THAN A HUMAN HAVING A STRUCTURED ANGPTL8 GENE | 2017 |
|
RU2742354C2 |
| NON-HUMAN ANIMALS CONTAINING HUMANISED ALBUMIN LOCUS | 2020 |
|
RU2815514C2 |
| METHODS AND COMPOSITIONS FOR ASSESSMENT OF MEDIATED CRISPR/CAS DESTRUCTION OR CUTOUT AND INDUCED CRISPR/CAS RECOMBINATION WITH EXOGENEOUS DONOR NUCLEIC ACID IN VIVO | 2018 |
|
RU2782356C2 |
| ANIMALS OTHER THAN HUMAN, INCLUDING HUMANIZED TTR LOCUS, AND APPLICATION METHODS | 2018 |
|
RU2784927C1 |
| FGF21 MIMETIC ANTIBODIES AND THEIR APPLICATION METHODS | 2018 |
|
RU2774368C2 |
| DNA ANTIBODY CONSTRUCTIONS FOR USE AGAINST LYME DISEASE | 2017 |
|
RU2813829C2 |
